Fig. 5From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCDistribution of acquired resistance mechanism of patients who progressed from A EGFR-TKI monotherapy (T) or B EGFR-TKI with bevacizumab (A+T)Back to article page